Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and GLENN LARKIN

Exelixis Stock Flashes Improved Relative Price Strength With Upgrade

Exelixis had its Relative Strength (RS) Rating upgraded from 70 to 74 Tuesday -- a welcome improvement, but still shy of the 80 or higher score you prefer to see.

As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.

This unique rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.

History reveals that the best stocks tend to have an RS Rating of above 80 in the early stages of their moves. See if Exelixis can continue to rebound and hit that benchmark.

Looking For Winning Stocks? Try This Simple Routine

Exelixis broke out earlier, but has fallen back below the prior 20.56 entry from a flat base. It has not fallen over 7%, so the base is still in play, and one to keep on your watchlist.

Earnings growth increased in the company's latest report from -38% to 11%, but revenue fell from 15% to 12%.

The company earns the No. 38 rank among its peers in the Medical-Biomed/Biotech industry group. Arcturus Therapeutics and Kiniksa Pharmaceuticals are also among the group's highest-rated stocks.

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.